Overview

To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria

Status:
NOT_YET_RECRUITING
Trial end date:
2031-08-30
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, dose-escalation, exploratory study to evaluate the safety, tolerability, and efficacy of a single administration of GS1168 Injection in Chinese adult phenylketonuria (PKU) with PAH mutation.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Gritgen Therapeutics Co., Ltd.